483 Roundup: Three Firms Cited for Labeling, Complaints, Safety Problems

The FDA flagged three U.S. facilities for a variety of noncompliances observed by agency investigators during inspections, including issues with labeling, failure to properly handle complaints and reporting of adverse events.
Source: Drug GMP Report